Trubion Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
July 30 2008 - 4:00PM
PR Newswire (US)
SEATTLE, July 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals,
Inc. (NASDAQ:TRBN), today announced that Dr. Peter A. Thompson,
president, CEO and chairman, will present an overview of the
company at the Bank of America 2008 Specialty Pharmaceuticals
Conference on Thursday, Aug. 7 at 8:45 a.m. This conference will be
held at the Southampton Inn in Long Island, N.Y. The presentation
will be available via audio webcast at
http://www.veracast.com/webcasts/bas/specpharma08/id72102172.cfm
and will be available in the investors section of Trubion's Web
site, http://investors.trubion.com/. About Trubion Trubion is a
biopharmaceutical company that is creating a pipeline of novel
protein therapeutic product candidates to treat autoimmune and
inflammatory diseases and cancer. The company's mission is to
develop a variety of first-in-class and best-in-class product
candidates, customized for optimal safety, efficacy and convenience
that it believes may offer improved patient experiences. Trubion's
current product candidates are novel single-chain protein, or
SMIP(TM), therapeutics, and are designed using its custom drug
assembly technology. Trubion's product pipeline includes
CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune
and inflammatory diseases, developed under the company's Wyeth
collaboration. Trubion's product pipeline also includes Trubion's
proprietary product candidate, TRU-016, a novel CD37-targeted
therapy for the treatment of B-cell malignancies that is currently
in Phase 1/2 clinical evaluation. In addition to Trubion's current
product candidates, the company is also developing additional
alliance and proprietary product candidates that build on its
product development experience. More information is available in
the investors section of Trubion's website: investors.trubion.com.
TRBN-G DATASOURCE: Trubion Pharmaceuticals, Inc. CONTACT: Jim
DeNike, Senior Director, Corporate Communication of Trubion
Pharmaceuticals, Inc., +1-206-838-0500, ; or Amy Petty, Senior
Account Executive of Waggener Edstrom Worldwide Healthcare,
+1-617-576-5788, , for Trubion Pharmaceuticals, Inc. Web site:
http://investors.trubion.com/
Copyright
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jul 2023 to Jul 2024